Addex provisional 2024 third quarter results showed net loss compared to second quarter 2024

Nine-month results remain on track for net profit ad hoc announcement pursuant to art. 53 lr geneva, switzerland, november 11, 2024 - addex therapeutics (six/nasdaq: adxn), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its provisional third quarter net results decreased significantly compared to the second quarter 2024.
ADXN Ratings Summary
ADXN Quant Ranking